ARCHIVES

Selumetinib Plus Docetaxel Effective in KRAS-Mutant Disease

This article is from The Cancer Letter archive.

Vol. 36 No. 1 | January 25, 2013

Download PDF Visit The Full Archive

Related Articles

Young Investigators Hold Their Own

September 28, 1979

CMS Allows Medicare Payment for Eloxatin, But Says Review of New Agents Likely

May 23, 2003

Funding Opportunities

January 17, 2003

32% Rise In Breast Cancer Diagnosis In 1980s Explained By Increase In Mammography Screening

September 21, 1990

Groups Advise NCI On “Investment Opportunities”

June 28, 1996

Lung, Head & Neck Treatment Advances Reported At ASCO Annual Meeting

May 27, 1977